Since 2012, the US Food and Drugs Administration have approved the use of daily Truvada (tenofovir co-formulated with emtricitabine) as pre-exposure prophylaxis (PrEP) for reducing the risk of sexual transmission of HIV infection. If PrEP were to be available as a biomedical intervention in the UK, healthcare providers would play a critical role in its … [Read more...]